Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade

Endocrinology

Volumn 143, Issue 11, 2002, Pages 4339-4348

  Gómez, Raúl ^c   Simón, Carlos ^a   Remohí, José ^a   Pellicer, Antonio ^a,b  

^a UNIVERSITY OF VALENCIA   (Spain)

^b HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^c Department of Obstetrics and Gynecology Hospital Universitario Dr Peset ^*

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN; MONOCLONAL ANTIBODY; SC 7269; SEMAXANIB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; FEMALE; GRANULOSA CELL; IMMUNOHISTOCHEMISTRY; LUTEAL CELL; MESENTERY; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARIECTOMY; OVARY; OVARY FOLLICLE; OVARY HYPERSTIMULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR BLOCKING; ZONA PELLUCIDA;

EID: 0036827816     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2002-220204     Document Type: Article

References (50)

1. Pellicer A, Albert C, Mercader A, Bonilla-Mussoles F, Remohi J, Simon C 1999 The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin (IL)-1β, IL-6 and vascular endothelial growth factor (VEGF). Fertil Steril 7:482-489
2. Agrawal R, Tan SL, Wild S, Sladkevicius P, Engmann L, Payne N, Bekir J, Campbell S, Conway G, Jacobs H 1999 Serum vascular endothelial growth factor concentrations in in-vitro fertilization cycles predict the risk of ovarian hyperstimulation syndrome. Fertil Steril 71:287-293
3. Abramov Y, Barac V, Nisman B, Schenker JG 1997 Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome. Fertil Steril 67:261-265
4. Chen CD, Wu MY, Chen HF, Chen SU, Ho HN, Yang YS 1999 Prognostic importance of serial cytokine changes in ascites and pleural effusion in women with severe ovarian hyperstimulation syndrome. Fertil Steril 72:286-292
5. Yan Z, Weich HA, Bernart W, Breckwoldt M, Neulen J 1993 Vascular endothelial growth factor (VEGF) messenger ribonucleic acid (mRNA) expression in luteinized human granulosa cells in vitro. J Clin Endocrinol Metab 77:1723-1725
6. Neulen J, Yan Z, Raczek S, Weindel K, Keck C, Weich HA, Marme D, Breckwoldt M 1995 Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/VP factor in human granulosa cells: Importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 80:1967-1971
7. Gordon JD, Mesiano S, Zaloudek CJ, Jaffe RB 1996 Vascular endothelial growth factor localization in human ovary and fallopian robes tubes: Possible role in reproductive function and ovarian cyst formation. J Clin Endocrinol Metab 81:353-359
8. Otani N, Minami S, Yamoto M, Shikone T, Otani H, Nishiyama R, Otani T, Nakano R 1999 The vascular endothelial growth factor/fms-like tyrosine kinase system in human ovary during the menstrual cycle and early pregnancy. J Clin Endocrinol Metab 84:3845-3851
9. Yamamoto S, Konishi I, Tsuruta Y, Nanbu K, Mandai M, Kuroda H, Matsushita K, Hamid AA, Yura Y, Mori T 1997 Expression of vascular endothelial growth factor (VEGF) during folliculogenesis and corpus luteum formation in the human ovary. Gynecol Endocrinol 11:371-381
10. Goldsman MP, Pedram A, Dominguez CE, Ciuffardi I, Levin E, Asch RH 1995 Increased capillary permeability induced by human follicular fluid: A hypothesis for an ovarian origin of the hyperstimulation syndrome. Fertil Steril 63:268-272
11. McClure N, Healy DL, Rogers PA, Sullivan J, Beaton L, Haning Jr RV, Connolly DT, Robertson DM 1994 Vascular endothelial cell growth factor as permeability agent in ovarian hyperstimulation syndrome. Lancet 344:235-236
12. Albert C, Garrido N, Rao CV, Remohí J, Simon C, Pellicer A 2002 The role of the endothelium in the pathogenesis of ovarian hyperstimulation syndrome. Mol Hum Reprod 8:409-418
13. Levin ER, Rosen GF, Cassidenti DL, Yee B, Meldrum D, Wisot A, Pedram A 1998 Role of vascular endothelial cell growth factor in ovarian hyperstimulation syndrome. J Clin Invest 102:1978-1985
14. Wei MH, Popescu NC, Lerman MI, Merrill MJ, Zimonjic DB 1996 Localization of the human vascular endothelial growth factor gene, VEGF, at chromosome 6p12. Hum Genet 97:794-779
15. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z 1999 Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13:9-22
16. Watkins RH, D'Angio CT, Ryan RM, Patel A, Maniscalco WM 1999 Differential expression of VEGF mRNA splice variants in newborn and adult hyperoxic lung injury. Am J Physiol 276:858-867
17. Olson TA, Mohanraj D, Carson LF, Ramakrishnan S 1994 VP factor gene expression in normal and neoplastic human ovaries. Cancer Res 54:276-280
18. Shima DT, Kuroki M, Deutsch U, Ng YS, Adamis AP, D'Amore PA 1996 The mouse gene for vascular endothelial growth factor, genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences. J Biol Chem 271:3877-3883
19. Burchardt M, Burchardt T, Chen MW, Shabsigh A, de la Taille A, Buttyan R, Shabsigh R 1999 Expression of messenger ribonucleic acid splice variants for the vascular endothelial growth factor in the penis of adult rats and humans. Biol Reprod 60:398-404
20. Phillips HS, Hains J, Leung DW, Ferrara N 1990 Vascular endothelial growth factor is expressed in rat corpus luteum. Endocrinology 127:965-967
21. De Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT 1992 The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255:989-991
22. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH 1994 Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269:26988-26995
23. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC 1995 Failure of blood island formation and vasculogenesis in Flk-1-deficient mice. Nature 376:62-66
24. Verheul HM, Hoekman K, Jorna AS, Smit EF, Pinedo HM 2000 Targeting vascular endothelial growth factor blockade: Ascites and pleural effusion formation. Oncologist 5(Suppl 1):45-50
25. Xu L, Yoneda J, Herrera C, Wood J, Killion JJ, Fidler IJ 2000 Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int J Oncol 16:445-454
26. Yukita A, Asano M, Okamoto T, Mizutani S, Suzuki H 2000 Suppresion of ascites formation and re-accumulation associated with human ovarian cancer by an anti-VPF monoclonal antibody in vivo. Anticancer Res 20:155-160
27. Kobayashi H, Okada, Asahina T, Gotoh J, Terao T 1998 The kallikrein-kinin system, but not vascular endothelial growth factor, plays a role in the increased VP associated with ovarian hyperstimulation syndrome. J Mol Endocrinol 20:363-374
28. Ujioka T, Matsuura, Kawano T, Okamura H 1997 Role of progesterone in capillary permeability in hyperstimulated rats. Hum Reprod 12:1629-1634
29. Khanna M, Chaturvedi UC, Sharma MC, Pandey VC, Mathur A 1990 Increased capillary permeability mediated by a Dengue virus-induced lymphokine. Immunology 69:449-453
30. Chomczynski P, Sacchi N 1987 Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159
31. Koos RD 1995 Increased expression of vascular endothelial growth/permeability factor in the rat ovary following an ovulatory gonadotropin stimulus: Potential roles in follicle rupture. Biol Reprod 52:1426-1435
32. Conn G, Bayne ML, Soderman DD, Kwok PW, Sullivan KA, Palisi TM, Hope DA, Thomas KA 1990 Amino acid and cDNA sequences of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor. Proc Natl Acad Sci USA 87:2628-2632
33. Dahl Lyons CA, Wheeler CA, Frishman GN, Hackett RJ, Seifer DB, Haning Jr RV 1994 Early and late presentation of the ovarian hyperstimulation syndrome: Two distinct entities with different risk factors. Hum Reprod 9:792-799
34. Doldi N, Bassan M, Fusi F, Ferrari A 1997 In controlled ovarian hyperstimulation, steroid production, oocyte retrieval, and pregnancy rate correlate with gene expression of vascular endothelial growth factor. J Assist Reprod Genet 14:589-592
35. Itskovitz-Eldor J, Kol S, Lewit N, Sealey JE 1997 Ovarian origin of plasma and peritoneal fluid prorenin in early pregnancy and in patients with ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 82:461-464
36. Schenker JG 1999 Clinical aspects of ovarian hyperstimulation syndrome. Eur J Gynecol Reprod Biol 85:13-10
37. Rizk B, Aboulghar M, Smitz J, Ron-El R 1997 The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Hum Reprod Update 3:255-266
38. Guo D, Jia Q, Song HY, Warren RS, Donner DB 1995 Vascular endothelial cell growth factor promotes tyrosine phosphorilation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation. J Biol Chem 270:6729-6733
39. Wu HM, Yuan Y, Zawieja DC, Tinsley J, Granger HJ 1999 Role of phospholipase C, protein kinase C, and calcium in VEGF-induced venular hyperpermeability. Am J Physiol 276:H535-H542
40. He H, Venema Vj, Gu X, Venema RC, Marrero MB, Caldwell RB 1999 Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through Flk-1/KDR activation of c-Src. J Biol Chem 274:25130-25135
41. Gille H, Kowalsky J, Li B, LeCouter J, Moffat B, Zioncheck TF, Pelletier N, Ferrara N 2001 Analysis of biological effects and signalling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem 276:3222-3230
42. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP, McMahon G 1999 SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 59:99-106
43. Mendel DB, Schreck RE, West DC, Li G, Strawn LM, Tanciongco SS, Vasile S, Shawver LK, Cherrington JM 2000 The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. Clin Cancer Res 6:4848-4858
44. Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, McMahon G, Waltenberger J, Voelkel NF, Tuder RM 2001 Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 15:427-438
45. Brekken RA, Overholser JP, Stastny VA, Waltenberger J, Minna JD, Thorpe PE 2000 Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 60:5117-5124
46. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Curwen JO, Hennequin LF, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF 2000 ZD4190: An orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res 60:970-975
47. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rosel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F 2000 PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60:2178-2189
48. Kozin SV, Boucher Y, Hicklin DJ, Bohlen P, Jain RK, Suit HD 2001 Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res 61:39-44
49. Bold G, Altmann KH, Frei J, Lang M, Manley PW, Traxler P, Wietfeld B, Bruggen J, Buchdunger E, Cozens R, Ferrari S, Furet P, Hofmann F, Martiny-Baron G, Mestan J, Rosel J, Sills M, Stover D, Acemoglu F, Boss E, Emmenegger R, Lasser L, Masso E, Roth R, Schlachter C, Vetterli W 2000 New anilinophthalazines as a potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis. J Med Chem 43:2310-231
50. Vajkoczy P, Menger MD, Vollmar B, Schilling L, Schmiedek P, Hirth KP, Ullrich A, Fong TA 1999 Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy. Neoplasia 1:31-41